226 related articles for article (PubMed ID: 350397)
21. Chemoimmunotherapy of small cell bronchogenic carcinoma.
Holoye PY; Samuels ML; Smith T; Sinkovics JG
Cancer; 1978 Jul; 42(1):34-40. PubMed ID: 208755
[TBL] [Abstract][Full Text] [Related]
22. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
23. Combined chemotherapy for unresectable carcinoma of the lung: a randomized trial.
Eridani S; Burdick L; Maggio L; Cunietti E; Periti M; Arosio A; Perrone G
Int J Clin Pharmacol Biopharm; 1978 Oct; 16(10):482-5. PubMed ID: 81190
[TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients.
Samson MK; Baker LH; Fraile RJ; Izbicki RM; Vaitkevicius VK
Cancer Treat Rep; 1977; 61(1):59-64. PubMed ID: 67895
[TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy in metastatic or recurrent non-small cell bronchogenic carcinoma. 5-year results.
Ojala A; Nikkanen VN; Paloheimo S; Palojoki A; Thölix E
Strahlentherapie; 1983 Dec; 159(12):775-7. PubMed ID: 6364459
[TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy and radiation therapy for small cell carcinoma of the lung.
Maurer LH; Tulloh M; Eagan RT; Forcier RJ; House R
Cancer Chemother Rep 3; 1973 Mar; 4(2):171-6. PubMed ID: 4354041
[No Abstract] [Full Text] [Related]
27. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
[TBL] [Abstract][Full Text] [Related]
28. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.
Vogelzang NJ; Trowbridge RC; Frenning DH; Theologides A; Kennedy BJ; Kelly DR; Ewing SL; Vosika GJ
Cancer Treat Rep; 1980; 64(8-9):997-1000. PubMed ID: 6256076
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy of bronchogenic carcinoma. I. Non-oat cell.
Livingston RB
Cancer Treat Rev; 1977 Sep; 4(3):153-65. PubMed ID: 73419
[No Abstract] [Full Text] [Related]
31. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H
Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258
[TBL] [Abstract][Full Text] [Related]
33. Cellular immune reactions in patients with bronchogenic carcinoma before and after radio-, chemo- and immunotherapy.
Gropp C; Havemann K
Z Immunitatsforsch Immunobiol; 1977 Sep; 153(3):236-47. PubMed ID: 930234
[No Abstract] [Full Text] [Related]
34. [Chemotherapy of small cell carcinomas of the lung].
Flicker M; Neumann M
Wien Med Wochenschr; 1983 Aug; 133(15-16):397-402. PubMed ID: 6314680
[TBL] [Abstract][Full Text] [Related]
35. [Antineoplastic chemotherapy for bronchial carcinoma].
Tanneberger S
Arch Geschwulstforsch; 1985; 55(1):63-71. PubMed ID: 2985017
[TBL] [Abstract][Full Text] [Related]
36. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
37. A phase II clinical trial evaluating the use of two sequential, four-drug combination chemotherapy regimens in ambulatory bronchogenic adenocarcinoma patients.
Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Lenz C
Am J Clin Oncol; 1992 Dec; 15(6):480-6. PubMed ID: 1449109
[TBL] [Abstract][Full Text] [Related]
38. Non-specific immunostimulation in bronchogenic cancer.
Israel L
Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
[No Abstract] [Full Text] [Related]
39. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
40. Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma.
Millar JW; Hunter AM; Wightman AJ; Horne NW
Eur J Respir Dis; 1980 Jun; 61(3):162-6. PubMed ID: 7439279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
